WASHINGTON (AP) — Federal health officials have approved a new injectable drug to treat patients who have been exposed to the deadly toxin anthrax.
The Food and Drug Administration said it approved Anthim on Friday to treat inhalation anthrax, which can cause serious injury and death. The condition occurs when anthrax bacterial spores are inhaled.
Because anthrax is a potential bioterrorism weapon the U.S. government has been funding the development and production of therapies.
Anthim was developed by Elusys Therapeutics Inc. of Pine Brook, New Jersey, with support from the Biomedical Advanced Research and Development Authority. The government agency stockpiles vaccines, drugs and equipment for use during pandemics and other health emergencies.
Most Read Business Stories
- GM and Ventec relying on Woodinville supplier in venture to rapidly make more ventilators for coronavirus patients
- Amazon confirms Seattle-area warehouse employee has coronavirus
- The U.S. tried to build a new fleet of ventilators. The mission failed.
- Amazon to begin taking employees' temperatures daily in attempt to slow coronavirus
- Bosses panic-buy spy software to keep tabs on remote workers